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Campylobacteriosis is a collective description for infectious diseases caused by members of the bacterial
genus Campylobacter. The only form of campylobacteriosis of major public health importance is Campylo-
bacter enteritis due to C. jejuni and C. coli. Research and control efforts on the disease have been con-
ducted more often in developed countries than developing countries. However, because of the increasing
incidence, expanding spectrum of infections, potential of HIV-related deaths due to Campylobacter, and
the availability of the complete genome sequence of C. jejuni NCTC 11168, interest in campylobacteriosis
research and control in developing countries is growing. We present the distinguishing epidemiologic and
clinical features of Campylobacter enteritis in developing countries relative to developed countries.
National surveillance programs and international collaborations are needed to address the substantial
gaps in the knowledge about the epidemiology of campylobacteriosis in developing countries. 
ampylobacteriosis is a collective description for infec-
tious diseases caused by members of the bacterial genus
Campylobacter. The only form of campylobacteriosis of major
public health importance is Campylobacter  enteritis due to
C. jejuni and C. coli (1). The rate of Campylobacter infections
worldwide has been increasing, with the number of cases often
exceeding those of salmonellosis and shigellosis (2). This
increase, as well as the expanding spectrum of diseases caused
by the organisms, necessitates a clearer understanding of the
epidemiology and control of campylobacteriosis.
Surveillance and control of diseases of public health
importance in developing countries have focused on diseases
such as malaria, tuberculosis, trypanosomiasis, onchocerciasis,
and schistosomiasis (3). Programs for diarrhea and acute respi-
ratory illness also exist (4). These programs have extensive
support from the World Health Organization (WHO).
Campylobacter is one of the most frequently isolated bac-
teria from stools of infants with diarrhea in developing coun-
tries—a result of contaminated food or water (5,6). However,
national surveillance programs for campylobacteriosis gener-
ally do not exist in most developing countries despite the sub-
stantial burden of disease. Most data available on
campylobacteriosis in developing countries were collected as a
result of support provided by WHO to many laboratories in
developing countries, including grants for epidemiologic stud-
ies and Lior serotyping antisera provided by the Public Health
Service of Canada (5,7). The number of reviews and updates
on human campylobacteriosis in developed countries (8-11) is
greater than that for developing countries (5,6). This disparity
may be because Campylobacter-associated diarrhea in devel-
oping countries is not pathogenic in patients >6 months of age.
However, a community-based longitudinal study provided evi-
dence that infection could be pathogenic beyond the first 6
months of life in developing countries (12). Furthermore, the
sequencing and publication of the complete genome of
C. jejuni NCTC 11168 have heralded a renaissance of interest
in this organism, offering researchers worldwide, including in
developing countries, novel ways to contribute to the under-
standing the organism’s biology (13). Thus, to promote
research and control of campylobacteriosis in developing
countries, review information on human campylobacteriosis in
these countries is urgently needed. We present the distinguish-
ing features of campylobacteriosis in developing countries rel-
ative to developed countries.
Incidence
Generally, developing countries do not have national sur-
veillance programs for campylobacteriosis; therefore, inci-
dence values in terms of number of cases for a population do
not exist. Availability of national surveillance programs in
developed countries has facilitated monitoring of sporadic
cases as well as outbreaks of human campylobacteriosis (2,8-
11). Most estimates of incidence in developing countries are
from laboratory-based surveillance of pathogens responsible
for diarrhea. Campylobacter isolation rates in developing
countries range from 5 to 20% (6).  Table 1 shows isolation
rates for some countries according to WHO regions from stud-
ies of diarrhea in children <5 years old (14-25). Despite the
lack of incidence data from national surveys, case-control
community-based studies have provided estimates of 40,000 to
60,000/100,000 for children <5 years of age (6,12). In con-
trast, the figure for developed countries is 300/100,000 (8).
Estimates in the general population in developing and devel-
oped countries are similar, approximately 90/100,000 (5,6,8),
confirming the observation that campylobacteriosis is often a
1Portions of this review were presented at the World Health Organiza-
tion Consultation on the Increasing Incidence of Campylobacteriosis in
Humans, Copenhagen, Denmark, November 1-25, 2000. In addition,
relevant emerging information from the 11th International Workshop on
Campylobacter, Helicobacter and Related Organisms, held in Freiburg,
Germany, September 1-5, 2001, are included.
*University of Lagos, Idi-Araba, Lagos, Nigeria; and †University of
Venda for Science and Technology, Thohoyandon, South Africa
CSYNOPSIS
238 Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002
pediatric disease in developing countries. The isolation and
incidence rates in some developing countries have increased
since their initial reports (17). This increase has often been
attributed to improved diagnostic methods, but an actual
increase in incidence was observed in Campylobacter-associ-
ated diarrhea in the Caribbean island of Curaçao (26).
Age of Infection
In developing countries, Campylobacter is the most com-
monly isolated bacterial pathogen from <2-year-old children
with diarrhea (Table 2). The disease does not appear to be
important in adults. In contrast, infection occurs in adults and
children in developed countries. Poor hygiene and sanitation
and the close proximity to animals in developing countries all
contribute to easy and frequent acquisition of any enteric
pathogen, including Campylobacter. Although infections in
infants appear to decline with age (Table 2), a comprehensive
community-based cohort study in Egypt has shown that infec-
tion could be pathogenic regardless of the age of the child,
underscoring the need for strengthening prevention and con-
trol strategies for campylobacteriosis (12).
Polymicrobial Infections Involving Campylobacter
Campylobacter  is isolated relatively frequently with
another enteric pathogen in patients with diarrhea in develop-
ing countries. In some cases half or more patients with
Campylobacter  enteritis also had other enteric pathogens
(23,30). Organisms reported include Escherichia coli, Salmo-
nella, Shigella, Giardia lamblia, and Rotavirus. Polymicrobial
infections involving Campylobacter are rare in developed coun-
tries (5,6).
Isolation of Campylobacter in Healthy Children
The recovery of Campylobacter organisms from children
without diarrhea is common in developing countries. In some
reports the isolation rates for symptomatic and asymptomatic
children were not statistically significant. Values as high as
14.9% in controls have been observed (14). Acquisition of the
pathogen because of poor sanitation and contact with animals
early in life may explain the isolation from healthy children.
Campylobacter is not frequently recovered from asymptom-
atic persons in developed countries, as observed in the Nether-
lands, where a 0.5% isolation rate has been reported (9).
Seasonal Variation
In developing countries, Campylobacter enteritis has no
seasonal preference; in contrast, in developed countries epi-
demics occur in summer and autumn (2). Isolation peaks vary
from one country to another and also within countries
(12,31,32). The lack of seasonal preference may be due to lack
of extreme temperature variation as well as lack of adequate
surveillance for epidemics (5,6).
Distribution of Campylobacter Species
C. jejuni and C. coli are the two main species isolated in
developing countries. The isolation rate of C. jejuni exceeds
that of C. coli, similar to observations in most developed coun-
tries (8,9). Lior biotyping and serotyping methods have been
used in developing countries to subtype strains of C. jejuni and
C. coli (5,6). Table 3 shows the distribution of the subtypes
from three African countries. Biotype I was the most common,
followed by biotype II. The prevalence of specific serotypes
only in symptomatic children may indicate virulence traits or
treatment, in cases of gastroenteritis (33). Furthermore, corre-
lation between biotypes and serotypes isolated from humans
and animals indicates that campylobacteriosis is zoonotic (36).
Penner serotyping scheme and DNA-based typing, extensively
Table 1. Isolation rates of Campylobacter from diarrhea specimens 
from <5-year-olds in selected developing countries
WHO region and country Isolation rate (%) Reference
Africa
Algeria 17.7 14
Cameroon 7.7 15
Ethiopia 13.8 16
Nigeria 16.5 17
Tanzania 18.0 18
Zimbabwe 9.3 19
Americas
Brazil 9.9 20
Guatemala 12.1 21
Eastern Mediterranean
Egypt 9.0 12
Jordan 5.5 22
Southeast Asia
Bangladesh 17.4 23
Thailand 13.0 24
Western Pacific
Laos 12.1 25
WHO = World Health Organization.
Table 2. Age of patients with Campylobacter infection in selected 
developing countries
Countries (ref.) Age of infection (months)
Nigeria (17) 24
Tanzania (18) 18
China (27) 12-24
Thailand (28) <12 (18.8%)
12-23 (12.3%)
24-59 (10.3%)
Bangladesh (29) ≤ 12 (38.8%)
>12 (15.9%)
Egypt (12) 0-5 (8%)
6-11 (14%)
12-23 (4%)Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 239
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used in developed countries, have been proposed for use in
developing countries (37).
Species other than C. jejuni and C. coli—such as C. upsa-
liensis, C. concisus, and aerotolerant campylobacters (Arco-
bacter)—may also be of pathogenic importance; however,
diagnostic capacities to determine their distribution are lacking
in developing countries (38). These other Campylobacter spe-
cies constitute over 50% of campylobacters isolated at the Red
Cross Children’s Hospital, Cape Town, South Africa, for
example. (A method termed the Cape Town Protocol is used to
isolate  Campylobacter  species at this facility [39]). This
higher incidence is also supported by a 16% isolation rate of
Arcobacter species in a 4-month survey from poultry drainage
water in Lagos, Nigeria (40).
Antibiotic Resistance in Campylobacter Isolates
Campylobacter enteritis is a self-limiting disease, and anti-
microbial therapy is not generally recommended. However,
antimicrobial agents are recommended for extraintestinal
infections and for treating immunocompromised persons.
Erythromycin and ciprofloxacin are drugs of choice (10). The
rate of resistance to these drugs is increasing in both developed
and developing countries, although the incidence is higher in
developing countries. Use of these drugs for infections other
than gastroenteritis and self-medication are often the causes of
resistance in developing countries; in developed countries,
resistance is due to their use in food animals and travel to
developing countries. The increase in erythromycin resistance
in developed countries is often low and stable at approxi-
mately 1% to 2%; this is not true for developing countries
(41,42). For example, in 1984, 82% of Campylobacter strains
from Lagos, Nigeria, were sensitive to erythromycin; 10 years
later, only 20.8% were sensitive (17). In addition, resistance to
another macrolide, azithromycin, was found in 7% to 15% of
Campylobacter isolates in 1994 and 1995 in Thailand (43).
The increasing rate of resistance to the fluoroquinolone, cipro-
floxacin limits its clinical usefulness. In Thailand, ciprofloxa-
cin resistance among Campylobacter species increased from
zero before 1991 to 84% in 1995 (43). Recent data have shown
a marked increase in resistance to quinolones in developed
countries (41,42,44-46) (Table 4).
Campylobacter as a Cause of Travelers’ Diarrhea
Travel to a developing country is a risk factor for acquiring
Campylobacter-associated diarrhea. The diarrhea is more
severe, and strains are associated with antibiotic resistance
(47,48). Furthermore, campylobacteriosis acquired abroad
contributes to the number of cases reported in developed coun-
tries (49). Among Finnish tourists visiting Morocco, the dis-
ease was more prevalent in winter months (50).
Clinical Features
The clinical spectrum of Campylobacter enteritis ranges
from a watery, nonbloody, noninflammatory diarrhea to a
severe inflammatory diarrhea with abdominal pain and fever.
Disease is less severe in developing countries than in devel-
oped countries (5,6). In developed countries, disease is charac-
terized by bloody stool, fever, and abdominal pain that is often
more severe than that observed for Shigella and Salmonella
infections. In developing countries the features reported are
watery stool, fever, abdominal pain, vomiting, dehydration,
and presence of fecal leukocytes; patients are also often under-
weight and malnourished (12,31,51). In Lagos, Nigeria,
Campylobacter enteritis is characterized by a history of watery
offensive-smelling stool lasting <5 days (51). 
Guillain-Barré Syndrome
Guillain-Barré Syndrome (GBS) is an autoimmune disor-
der of the peripheral nervous system, which is characterized
by acute flaccid paralysis. C. jejuni infection is the most fre-
quently identified infection preceding GBS (52). In the devel-
oping world, sporadic GBS cases associated with C. jejuni
infection have been reported from Curaçao, China, India, and
South Africa (26,53-55). A comparative study between
Curaçao and southwest Netherlands indicated that disease in
Curaçao was more severe, had a higher incidence of preceding
gastroenteritis, and had greater seasonal fluctuation (26). Sero-
type O:19 is most prevalent worldwide, although other sero-
types, such as O:1, O:2, O:57, O:16, O:23, O:37, O:41, and
Table 3. Distribution of Campylobacter jejuni and C. coli biotypes and serotypes in three African countries
Countries (ref.)
Biotypes
Serotypes
C. jejuni C. coli
I II III IV I II
Nigeria (33) 52.5 28.7 - - 9.9 8.9 1, 8, 11, 20, 28, 45 
Central African Republic (34) 31.9 11.0 2.4 - 44.0 11.5 -
South Africa (35) 95.4 1.5 - - 3.1 4, 2, 12, 19, 23, 36
Table 4. Trends in Resistance to Ciprofloxacin by Campylobacter 
jejuni in selected developed countries up to year 2000
Country Period
Resistance strains (%)
Ref. Initial Year 2000
Freiburg, Germany 1992-2000 22 32 41
Styria, Austria 1996-2000 25.2 40.2 42
England and 
Wales, UK
1993-2000 10 14.8 44
Philadelphia, USA 1995-2000 <10 36 45
Oslo, Norway 1988-2000 6.1 36 46SYNOPSIS
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O:44, have been reported (52). C. jejuni strain O:41 appears to
be restricted to Cape Town, South Africa, and represents a
genetically stable clone (55,56). Detailed studies of the role of
GBS in acute flaccid paralysis in developing countries, espe-
cially in polio-endemic areas, are needed.
Campylobacter Infection in the Setting of HIV
Campylobacter-associated diarrhea and bacteremia occur
in HIV/AIDS patients worldwide. The species isolated include
C. jejuni, C. coli, C. upsaliensis, Arcobacter butzleri, Helico-
bacter fennelliae, and H. cinaedii (57,58). The incidence of
clinical manifestations is higher than in HIV-negative patients,
with substantial mortality and morbidity. Furthermore, antibi-
otic resistance and recurrent infections have been observed
(59). The incidence of HIV/AIDS is higher in developing
countries than in developed countries and contributes substan-
tially to deaths among <5-year-old children in epidemic set-
tings (60). Thus, infants in developing countries are at risk of
impaired immunity to Campylobacter  enteritis. In addition,
HIV/AIDS can increase the number of cases of campylobacte-
riosis in the adult population in these countries. These observa-
tions further support the need for improved understanding of the
epidemiology of campylobacteriosis in developing countries.
Immunologic Aspects
In developing countries, such as Bangladesh, Thailand,
Central African Republic, and Mexico, healthy children and
adults are constantly exposed to Campylobacter antigens in
the environment. As a consequence, serum antibodies to
Campylobacter species develop very early in life in children in
developing countries, and the levels of such antibodies tend to
be much higher than those in children in the developed world
such as in the United States (61-64). In Nigeria, children who
had diarrhea and children who were healthy both had antibod-
ies in their sera that could agglutinate C. jejuni; the difference
in antibody responses between these groups of children was
not statistically significant (65). Thus, antibody responses
alone should be interpreted with caution in diagnosing Campy-
lobacter infections.
In spite of shortcomings in the use of antibodies for diag-
nosis, increase in the level of anti-flagellar antibody had an
inverse correlation with the rates of Campylobacter enteritis in
the Central African Republic (63). An age-related relationship
in the development of immunity to Campylobacter antigens
has also been suggested to account for the age-related declines
in the case-to-infection ratio and the period of excretion during
the convalescent phase (28,66).
Usually, as age increases, level of antibody tends to
increase. At the earliest stages in life (first 6 months), immu-
noglobulin (Ig) A, IgG, and IgM levels in response to Campy-
lobacter  infection are minimal, but thereafter increases are
observed in response to infection. The poor serologic response
during the first 6 months of life may be due either to a primary
response to Campylobacter or to the presence of maternal anti-
bodies via the placenta or breast milk.
Breast-feeding has been reported to play a role in C. jejuni-
induced diarrhea. It decreases the number of episodes and the
duration of diarrhea (67). In Algeria, exclusively breast-fed
infants had fewer symptomatic Campylobacter infections than
infants who were both breast-fed and bottle-fed (14).
Results of experimental observations among Mexican chil-
dren have also shown that immunity to Campylobacter after
primary infection may prevent bloody diarrhea from develop-
ing and subsequently prevent any disease from manifesting
(68). In the developed world, the epidemiology may be differ-
ent because most cases are usually primary infections with
more severe clinical manifestations, greater numbers of people
with bloody diarrhea (50%, as opposed to 15% in developing
countries), and a more prolonged duration of excretion
(approximately 15 days, compared with 7 days in developing
countries) (28). The widespread immunity seen among adults
in developing countries is absent in adults in developed coun-
tries (64).
Sources of Human Campylobacteriosis
Campylobacter  infection is hyperendemic in developing
countries. The major sources of human infections are environ-
mental contamination and foods. Human-to-human transmis-
sion as a result of prolonged convalescent-phase excretion and
high population density have also been suggested (5,12),
although observations from developed countries show these
are less likely factors (2).
Environmental Contamination
Wild birds as well as domestic and companion animals are
known reservoirs for Campylobacter species, and shedding of
the bacteria from them causes contamination of the environ-
ment. C. jejuni and C. coli have been isolated from chickens,
goats, sheep, and pigs in developing countries (69,70). Strains
isolated from human and chickens were phenotypically and
genotypically correlated, confirming that chickens are an
important source of human campylobacteriosis in developing
countries (36). Poultry is also an important source of campylo-
bacteriosis in developed countries. Extensive epidemiologic
investigations have been done in those countries to identify
sources of contamination and routes of transmission to humans
to facilitate control efforts (71). Risk factors for acquiring
campylobacters in developing countries include presence of an
animal in the cooking area, uncovered garbage in cooking
areas, and lack of piped water (12).
Foods
Campylobacter-contaminated foods—the result of poor
sanitation—are an important potential source of infection in
humans. For example, campylobacters were isolated from
40% and 77% of retail poultry meat sold in Bangkok, Thai-
land, and Nairobi, Kenya, respectively (72,73). The serotypes
of the organisms isolated in Thailand were similar to those of
organisms isolated from humans. In Mexico City, a survey of
ready-to-eat roasted chickens showed that they wereEmerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 241
SYNOPSIS
contaminated with campylobacters (74). In developed coun-
tries, risk factors associated with foods include occupational
exposure to farm animals, consumption of raw milk or milk
products, and unhygienic food preparation practices (2). 
Estimates of Impact of Human
Campylobacteriosis in Developing Countries
The Disability Adjusted Life Year (DALY) is the basic unit
used in Burden of Disease (BoD) methodology to quantify the
impact of disease on a population (75). DALYs have been
applied in the Dutch population to measure the mean health
burden of Campylobacter-associated illness in the period
1990–1995 (76). The mean estimate was 1,400 DALYs per
year; the main determinants of health burden were acute gas-
troenteritis (440 DALYs), gastroenteritis-related mortality
(310 DALYs), and residual symptoms of GBS (340 DALYs).
Although data on DALYs due to campylobacteriosis in devel-
oping countries are not available, diarrhea, which is a clinical
manifestation of campylobacteriosis, was one of the top three
causes of death and disease in developing countries in 1990
(75). The disease is projected globally to remain one of the top
10 by 2020. (The burden of campylobacteriosis in developing
countries may increase by 2020 because HIV is projected to
move up to the 10th position from 28th by 2020.) Considering
the higher incidence of campylobacteriosis in developing
countries, DALYs for the disease in developing countries will
likely be higher than those of the Dutch population.
Conclusions
The incidence of human campylobacteriosis is increasing
worldwide and has attracted the attention of WHO (http://
www1.oecd.org/agr/prog/sum-copenhagen00.htm). Ssubstan-
tial gaps in knowledge about the epidemiology of campylobac-
teriosis in developing countries still exist. Present reported
estimates of incidence are based on isolation rates from labora-
tory- and community-based studies conducted from 1980 to
1995. When various socioeconomic and health changes in
developing countries are taken into account, these values may
have changed considerably. Thus, public health awareness
about the problem is needed, as are strengthened diagnostic
facilities for campylobacteriosis, with a view towards setting
up national surveillance programs. Such programs would
determine the incidence rates, epidemiologic risk factors,
interaction of HIV/AIDS and campylobacteriosis, seasonal
variation, current state of resistance to antimicrobial agents,
role of species other than C. jejuni and C. coli, and the role of
campylobacteriosis in GBS. Collaboration among researchers
in developed and developing countries needs to be strength-
ened, leading to development of regional centers of excel-
lence. Funding organizations should provide incentives for
North-South collaborations in Campylobacter research, as is
done in other diseases such as malaria and trypanosomiasis
that are endemic in some developing countries. All these
should contribute to understanding of the global epidemiology
of human campylobacteriosis.
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